Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016', provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted pipeline therapeutics. 

The report provides comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) 
- The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Overview 7
Therapeutics Development 8
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Stage of Development 8
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Therapy Area 9
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Indication 10
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Companies 14
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Universities/Institutes 17
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development 26
Amgen Inc. 26
AnGes MG, Inc. 27
F-star Biotechnology Limited 28
Kringle Pharma, Inc. 29
M3 Biotechnology, Inc. 30
Minerva Biotechnologies Corporation 31
Molecular Partners AG 32
ViroMed Co., Ltd. 33
Yooyoung Pharmaceutical Co., Ltd. 34
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles 35
beperminogene perplasmid - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
FS-101 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Gene Therapy to Activate HGF for Myocardial Infarction - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
MM-201 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
MP-0250 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
NK-4 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
rilotumumab - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
SL-186 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
SL-188 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
VM-202 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
YYB-101 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Projects 57
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products 59
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Featured News & Press Releases 60
Sep 20, 2016: F-star to present data on FS-101 at Upcoming AACR Conferences 60
Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy 60
Aug 02, 2016: VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease 61
Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 61
Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia 62
May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis 63
Apr 15, 2016: AnGes Completes Patient Enrollment for Phase 1/2 Clinical Trials of Gene Therapy with HGF Plasmid in Primary Lymphedema 64
Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study 64
Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma 65
Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer 66
Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference 67
Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer 68
Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia 69
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 69
Nov 24, 2014: Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 71

Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by Amgen Inc., H2 2016 26
Pipeline by AnGes MG, Inc., H2 2016 27
Pipeline by F-star Biotechnology Limited, H2 2016 28
Pipeline by Kringle Pharma, Inc., H2 2016 29
Pipeline by M3 Biotechnology, Inc., H2 2016 30
Pipeline by Minerva Biotechnologies Corporation, H2 2016 31
Pipeline by Molecular Partners AG, H2 2016 32
Pipeline by ViroMed Co., Ltd., H2 2016 33
Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016 34
Dormant Projects, H2 2016 57
Dormant Projects (Contd..1), H2 2016 58
Discontinued Products, H2 2016 59